Commentary - (2022) Volume 6, Issue 3
Received: 05-May-2022, Manuscript No. fsb-22-76093;
Editor assigned: 07-May-2022, Pre QC No. P-76093;
Reviewed: 14-May-2022, QC No. Q-76093;
Revised: 18-May-2022, Manuscript No. R-76093;
Published:
25-May-2022
, DOI: 10.37421/2577-0543.2022.6.126
Citation: Park, Jin-Woo. “Effect of Natural Compound Regulators of Cancer Cell Metabolism.” J Formul Sci Bioavailab 6 (2022): 127.
Copyright: © 2022 Park JW. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Neoplastic disorders are characterised by unchecked cell proliferation. It is generally known that energy metabolism needs to be reprogrammed in order to accommodate rapid cell growth and division. The "Warburg effect" or "aerobic glycolysis" provides a clear explanation of this idea. Glycolysis is regulated by activated oncogenes, mutant tumour suppressor genes, or altered genes that code for metabolic enzymes, however many elements of cellular metabolism still lack clear emerging cell signalling mechanisms. Early phases of carcinogenesis are when metabolic reprogramming takes place and results in changed metabolic profiles, making them an intriguing potential target for cancer chemoprevention and therapy. In this Atg5, a crucial autophagy gene that when inactivated speeds up the early stages of carcinogenesis, in his speech.
Expression of ENTPD1/CD39, an ecto-ATPase, is induced by the combination of Atg5 inactivation and KRAS activation. Extracellular ATP is changed from an immunostimulatory response—which is caused by this— to an immunosuppressive response—into adenosine. Targeting ENTPD1/ adenosinergic receptors is crucial for slowing down rapid oncogenesis. The importance of mitochondrial ribosomal proteins (MRPs) as metabolic and longevity regulators. MRP knockdown triggered mitonuclear protein imbalance, which extends lifespan in Caenorhabditis elegans as well as in mammalian cells. Altogether, MRPs represent an evolutionary conserved protein family expressed in different species. the second keynote speaker's discussion on the importance of autophagy in KRAS and BRAF-driven lung cancer. In RASdriven malignancies without Trp53, autophagy is required for mitochondrial function and lipid catabolism as evidenced by reduced fatty acid oxidation (FAO), decreased fatty acid oxidation (FAO), and greater susceptibility to FAO inhibition [1].
As a result, autophagy is essential for determining the fate of carcinomas and has specific metabolic functions depending on the oncogene and tumour suppressor genes involved. The attention on the metabolic role of hypoxia in cancer cells. Fast-growing tumours can be eliminated by targeting important pHi-regulating systems like Na+ -H+ Exchangers (NHE) or Na+ -dependent Bicarbonate Transporters (NBTs), according to Pouysse'gur. Janji emphasised the contribution of hypoxia-induced autophagy to tumour cell destruction by natural killers. In their research, hypoxia increased autophagy, which reduced the susceptibility of breast cancer cells to NK-mediated anti-tumor immune response. He proved that NK-derived granzyme B is destroyed by activated autophagy in the lysosomes of hypoxic cells, leading to to cancer cells that are less sensitive to NK-mediated killing. Presented reactive oxygen species (ROS) produced by mitochondria and a new paradigm for cancer treatment. The majority of scientists are concentrating on an anti-oxidant approach to treat cancer because ROS are necessary for the development and advancement of cancer. However, as cancer cells cannot live in such high quantities of ROS, high ROS levels cause cell death. Concentrated on this fact and used an approach that involved raising ROS levels and causing cancer cell death. He presented research demonstrating that anti-oxidant enzymes like SOD1 (superoxidedismutase 1) and GPX can be inhibited to cause high ROS levels (glutathione peroxidase). The p53 family proteins and talked about how those proteins affect the metabolism of tumour cells. His team discovered that p53 has a significant role in blocking NADPH-producing enzymes like glucose-6-phosphate dehydrogenase (G6PD) and malic enzyme. P53 controls the creation of NADPH, the metabolism of glucose and glutamine, and the formation of vital precursors by blocking these enzymes. Various highly specialised elements of energy metabolism in cancer cells piqued the interest of many experts [2].
In order to treat cancer, Professor Nissim Hay (University of Illinois at Chicago, USA) focuses on glucose metabolism. As many speakers before me have shown, even in aerobic settings, rapid glycolysis is a distinctive feature of cancer cells. Hexokinase (HK), which is involved in catalysing the first phase of glucose metabolism, was studied by Hay's team. HK2 is highly expressed in cancer cells. Here, Hay emphasised a successful and innovative cancer treatment using HK2 inhibition. The mammalian target of rapamycin (mTOR) signalling and gave fresh information about how mTOR signalling is controlled by its upstream and downstream effectors as well as how it interacts with other nutrient-sensing intracellular pathways. Additionally scientists discussed how certain natural substances, such as curcumin and resveratrol, could influence the metabolism of cancer cells and prevent mitochondrial dysfunctions. These substances are known to increase ROS, inhibit HIF-1a, modulate the expression of Bcl-2 family proteins, and decrease MMP [3]. They persuaded the audience that natural substances effectively control both metabolic and mitochondrial processes. The highlighted the importance of docosahexaenoic acid (DHA), a representative of v-3 polyunsaturated fatty acids abundantly present in fish and some plant seed oil with antioxidative, antiinflammatory and chemopreventive properties. He demonstrated inhibition of UVB-induced expression of cyclooxygenase (COX)-2 and nitric oxide (NOX)-4 in mouse skin by blocking the activation of NF-kB through inhibition of ERK- and p38 MAP kinase-mediated phosphorylation of MSK1 [4].
According to Professor Guido Bommer of the Catholic University of Louvain in Belgium, the p53-induced protein TIGAR is crucial for the metabolism of cancer cells. By showing that fructose 2,6-bisphosphate (F26BP) does not represent a physiological substrate for TIGAR and that its catalytic activity is 400 times lower than for 2,3-bisphosphoglycerate (2,3-BPG), which suggests that 2,3-BPG might play an as-yet-unrecognized role in metabolic control, Bommer identified and reevaluated the chemical function of TIGAR. Article focused on the activity of sarcoplasmic/endoplasmic reticulum Ca2+ ATPases (SERCA) related to glycolysis in damage-induced apoptosis. Ghibelli concluded that an ongoing glycolytic flux is necessary to maintain the activity of SERCA during the commitment phase of damage-induced apoptosis, and to attain the full finalization of the intrinsic apoptotic pathway. mitochondrial uncoupling protein 2 (UCP2), which influences how cells use their energy and produce ROS, is involved in the formation of tumours [5]. Furthermore, UCP2 overexpression activated AMPK signalling contemporaneous with a downregulation of HIF expression, controlling metabolic reprogramming in cancer cells. Cells overexpressing UCP2 switch their metabolism from glycolysis to oxidative phosphorylation.
None
The author shows no conflict of interest towards this article.
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Google Scholar, Crossref, Indexed at
Journal of Formulation Science & Bioavailability received 23 citations as per Google Scholar report
